-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
January 4, Step Pharmaceuticals announced that its controlling subsidiary, Zhejiang Tianyuan Biopharmaceutical Co., Ltd., had recently received a "Drug Clinical Trial Approval Notice" for the four-price influenza virus lysed vaccine approved by the State Drug Administration.The four-price influenza virus lysate vaccine is mainly used to stimulate the body to produce anti-influenza virus immunity, to prevent influenza caused by this strain. According to Minanet statistics, the amount of china's influenza virus lysation vaccine conversion approval in 2018 was 481.72 million yuan, and in 2019 China's influenza virus lyse vaccine conversion approval amounted to 967.2 million yuan, an increase of 101% over 2018.Up to now, the cumulative investment in research and development costs of the product is about 33.8137 million yuan. (
Sina Pharmaceutical News
)